Effect of Aldosterone Antagonism on Exercise Tolerance in Heart Failure With Preserved Ejection Fraction

Journal of the American College of Cardiology

Volumn 68, Issue 17, 2016, Pages 1823-1834

  Kosmala, Wojciech ^a,b,c   Rojek, Aleksandra ^a   Przewlocka Kosmala, Monika ^a,c   Wright, Leah ^b,c   Mysiak, Andrzej ^a   Marwick, Thomas H ^b,c  

^a WROCLAW MEDICAL UNIVERSITY   (Poland)

^b UNIVERSITY OF TASMANIA   (Australia)

^c BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

Author keywords

aldosterone antagonism; echocardiography; heart failure with preserved ejection fraction; left ventricular filling pressure

Indexed keywords

ALDOSTERONE ANTAGONIST; BRAIN NATRIURETIC PEPTIDE; CREATININE; GALECTIN 3; HEMOGLOBIN; PLACEBO; POTASSIUM; SODIUM; SPIRONOLACTONE; MINERALOCORTICOID ANTAGONIST;

AGED; ANAEROBIC THRESHOLD; ARTICLE; BLOOD PRESSURE; CONTROLLED STUDY; DIABETES MELLITUS; DRUG EFFECT; DYSPNEA; ESTIMATED GLOMERULAR FILTRATION RATE; EXERCISE TOLERANCE; FEMALE; FOLLOW UP; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE FILLING PRESSURE; HEMODYNAMIC PARAMETERS; HEMODYNAMICS; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MITRAL ANNULAR EARLY DIASTOLIC VELOCITY; MITRAL INFLOW VELOCITY; PRIORITY JOURNAL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; TERTIARY CARE CENTER; TREATMENT OUTCOME; BLOOD FLOW VELOCITY; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; HEART STROKE VOLUME; MITRAL VALVE; PATHOPHYSIOLOGY;

AGED; BLOOD FLOW VELOCITY; DOUBLE-BLIND METHOD; EXERCISE TOLERANCE; FEMALE; HEART FAILURE; HUMANS; MALE; MINERALOCORTICOID RECEPTOR ANTAGONISTS; MITRAL VALVE; PROSPECTIVE STUDIES; SPIRONOLACTONE; STROKE VOLUME;

EID: 84992758944     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2016.07.763     Document Type: Article

References (36)

1. 1 Somaratne, J.B., Berry, C., McMurray, J.J., Poppe, K.K., Doughty, R.N., Whalley, G.A., The prognostic significance of heart failure with preserved left ventricular ejection fraction: a literature-based meta-analysis. Eur J Heart Fail 11 (2009), 855–862.
2. 2 Owan, T.E., Hodge, D.O., Herges, R.M., Jacobsen, S.J., Roger, V.L., Redfield, M.M., Trends in prevalence and outcome of heart failure with preserved ejection fraction. N Engl J Med 355 (2006), 251–259.
3. 3 Mozaffarian, D., Benjamin, E.J., Go, A.S., et al. Heart disease and stroke statistics—2016 update: a report from the American Heart Association. Circulation 133 (2015), e38–e360.
4. 4 Shah, A.M., Pfeffer, M.A., The many faces of heart failure with preserved ejection fraction. Nat Rev Cardiol 9 (2012), 555–556.
5. 5 Yancy, C.W., Jessup, M., Bozkurt, B., et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62 (2013), e147–e239.
6. 6 McMurray, J.J., Adamopoulos, S., Anker, S.D., et al. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: The Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33 (2012), 1787–1847.
7. 7 Edelmann, F., Wachter, R., Schmidt, A.G., et al. Effect of spironolactone on diastolic function and exercise capacity in patients with heart failure with preserved ejection fraction: the Aldo-DHF randomized controlled trial. JAMA 309 (2013), 781–791.
8. 8 Pitt, B., Pfeffer, M.A., Assmann, S.F., et al. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370 (2014), 1383–1392.
9. 9 Redfield, M.M., Anstrom, K.J., Levine, J.A., et al. Isosorbide mononitrate in heart failure with preserved ejection fraction. N Engl J Med 373 (2015), 2314–2324.
10. 10 Redfield, M.M., Chen, H.H., Borlaug, B.A., et al. Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: a randomized clinical trial. JAMA 309 (2013), 1268–1277.
11. 11 Kosmala, W., Holland, D.J., Rojek, A., Wright, L., Przewlocka-Kosmala, M., Marwick, T.H., Effect of If-channel inhibition on hemodynamic status and exercise tolerance in heart failure with preserved ejection fraction: a randomized trial. J Am Coll Cardiol 62 (2013), 1330–1338.
12. 12 Pal, N., Sivaswamy, N., Mahmod, M., et al. Effect of selective heart rate slowing in heart failure with preserved ejection fraction. Circulation 132 (2015), 1719–1725.
13. 13 Borlaug, B.A., Paulus, W.J., Heart failure with preserved ejection fraction: pathophysiology, diagnosis, and treatment. Eur Heart J 32 (2011), 670–679.
14. 14 van Heerebeek, L., Hamdani, N., Handoko, M.L., et al. Diastolic stiffness of the failing diabetic heart: importance of fibrosis, advanced glycation end products, and myocyte resting tension. Circulation 117 (2008), 43–51.
15. 15 Zile, M.R., Brutsaert, D.L., New concepts in diastolic dysfunction and diastolic heart failure: part I: diagnosis, prognosis, and measurements of diastolic function. Circulation 105 (2002), 1387–1393.
16. 16 Zannad, F., McMurray, J.J., Krum, H., et al. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med 364 (2011), 11–21.
17. 17 Pitt, B., Zannad, F., Remme, W.J., et al., for the Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med 341 (1999), 709–717.
18. 18 Pitt, B., Remme, W., Zannad, F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 348 (2003), 1309–1321.
19. 19 Paulus, W.J., Tschöpe, C., Sanderson, J.E., et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur Heart J 28 (2007), 2539–2550.
20. 20 Nagueh, S.F., Appleton, C.P., Gillebert, T.C., et al. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. J Am Soc Echocardiogr 22 (2009), 107–133.
21. 21 Wasserman, K., Hansen, J., Sue, D., et al. Principles of Exercise Testing and Interpretation. 4th edition, 2005, Lippincott Williams & Wilkins, Philadelphia.
22. 22 American College of Sports Medicine. ACSM's Health-Related Physical Fitness Assessment Manual. 2013, Wolters Kluwer, Boston.
23. 23 Baba, R., Nagashima, M., Goto, M., et al. Oxygen uptake efficiency slope: a new index of cardiorespiratory functional reserve derived from the relation between oxygen uptake and minute ventilation during incremental exercise. J Am Coll Cardiol 28 (1996), 1567–1572.
24. 24 Lang, R.M., Badano, L.P., Mor-Avi, V., et al. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 28 (2015), 1–39.e14.
25. 25 Burgess, M.I., Jenkins, C., Sharman, J.E., Marwick, T.H., Diastolic stress echocardiography: hemodynamic validation and clinical significance of estimation of ventricular filling pressure with exercise. J Am Coll Cardiol 47 (2006), 1891–1900.
26. 26 Holland, D.J., Kumbhani, D.J., Ahmed, S.H., Marwick, T.H., Effects of treatment on exercise tolerance, cardiac function, and mortality in heart failure with preserved ejection fraction: a meta-analysis. J Am Coll Cardiol 57 (2011), 1676–1686.
27. 27 Edelmann, F., Tomaschitz, A., Wachter, R., et al. Serum aldosterone and its relationship to left ventricular structure and geometry in patients with preserved left ventricular ejection fraction. Eur Heart J 33 (2012), 203–212.
28. 28 Mottram, P.M., Haluska, B., Leano, R., Cowley, D., Stowasser, M., Marwick, T.H., Effect of aldosterone antagonism on myocardial dysfunction in hypertensive patients with diastolic heart failure. Circulation 110 (2004), 558–565.
29. 29 Izawa, H., Murohara, T., Nagata, K., et al. Mineralocorticoid receptor antagonism ameliorates left ventricular diastolic dysfunction and myocardial fibrosis in mildly symptomatic patients with idiopathic dilated cardiomyopathy: a pilot study. Circulation 112 (2005), 2940–2945.
30. 30 Kosmala, W., Przewlocka-Kosmala, M., Szczepanik-Osadnik, H., Mysiak, A., O'Moore-Sullivan, T., Marwick, T.H., A randomized study of the beneficial effects of aldosterone antagonism on LV function, structure, and fibrosis markers in metabolic syndrome. J Am Coll Cardiol Img 4 (2011), 1239–1249.
31. 31 Zannad, F., Alla, F., Dousset, B., Perez, A., Pitt, B., for the RALES Investigators. Limitation of excessive extracellular matrix turnover may contribute to survival benefit of spironolactone therapy in patients with congestive heart failure: insights from the Randomized Aldactone Evaluation Study (RALES). Circulation 102 (2000), 2700–2706.
32. 32 Iraqi, W., Rossignol, P., Angioi, M., et al. Extracellular cardiac matrix biomarkers in patients with acute myocardial infarction complicated by left ventricular dysfunction and heart failure: insights from the Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study (EPHESUS) study. Circulation 119 (2009), 2471–2479.
33. 33 Shah, A.M., Claggett, B., Sweitzer, N.K., et al. Prognostic importance of impaired systolic function in heart failure with preserved ejection fraction and the impact of spironolactone. Circulation 132 (2015), 402–414.
34. 34 Chase, P.J., Kenjale, A., Cahalin, L.P., et al. Effects of respiratory exchange ratio on the prognostic value of peak oxygen consumption and ventilatory efficiency in patients with systolic heart failure. J Am Coll Cardiol HF 1 (2013), 427–432.
35. 35 Ingle, L., Witte, K.K., Cleland, J.G., Clark, A.L., The prognostic value of cardiopulmonary exercise testing with a peak respiratory exchange ratio of <1.0 in patients with chronic heart failure. Int J Cardiol 127 (2008), 88–92.
36. 36 AbouEzzeddine, O.F., Haines, P., Stevens, S., et al. Galectin-3 in heart failure with preserved ejection fraction: a RELAX trial substudy (Phosphodiesterase-5 Inhibition to Improve Clinical Status and Exercise Capacity in Diastolic Heart Failure). J Am Coll Cardiol HF 3 (2015), 245–252.